Company Analysis
Sign in

Elicio Therapeutics, Inc. (ELTX)

Nasdaq: ELTX · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2014
Full chart Alerts Compare
Grade3.8
◀ Past 2.7● Present 3.6▶ Future 4.6
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

30 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Elicio Therapeutics, Inc.’s names, not what it holds today.

Patents granted
30
30 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and 2 in 2023
Applications published
59
6 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals8
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Angion Biomedica Corp. a former name
US, as the owner printed on each patent
26 granted
32 published
ANGION BIOMEDICA CORP. a former name
named as the applicant on its applications, in US
0 granted
16 published
Elicio Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
11 published
Elicio Therapeutics, Inc. its own name
US, as the owner printed on each patent
4 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 29, 202512,370,245ALK polypeptides and methods of use thereofPharmaceuticalsElicio Therapeutics, Inc.
Mar 11, 202512,247,052CpG amphiphiles and uses thereofPharmaceuticalsElicio Therapeutics, Inc.
Nov 12, 202412,138,301Compounds including a mutant KRAS sequence and a lipid and uses thereofPharmaceuticalsElicio Therapeutics, Inc.
Apr 11, 202311,623,002ALK polypeptides and methods of use thereofPharmaceuticalsElicio Therapeutics, Inc.
Jan 3, 202311,542,256Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitorsOrganic fine chemistryAngion Biomedica Corp.
Nov 22, 202211,504,359Antifibrotic compounds and uses thereofPharmaceuticalsAngion Biomedica Corp.
Oct 4, 202211,459,319Cytochrome P450 inhibitors and uses thereofPharmaceuticalsAngion Biomedica Corp.
Sep 6, 202211,434,234Methods and agents for treating diseasePharmaceuticalsAngion Biomedica Corp.
Jun 28, 202211,370,783Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazoleOrganic fine chemistryAngion Biomedica Corp.
Jan 26, 202110,899,750Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activityPharmaceuticalsAngion Biomedica Corp.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0325644ALK POLYPEPTIDES AND METHODS OF USE THEREOFPharmaceuticalsElicio Therapeutics, Inc.
Oct 2, 20252025/0302970USES OF AMPHIPHILES IN IMMUNE CELL THERAPY AND COMPOSITIONS THEREFORPharmaceuticalsElicio Therapeutics, Inc.
Aug 7, 20252025/0249107COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOFPharmaceuticalsElicio Therapeutics, Inc.
May 29, 20252025/0171507CPG AMPHIPHILES AND USES THEREOFPharmaceuticalsElicio Therapeutics, Inc.
May 1, 20252025/0134992COMPOSITIONS CONTAINING POLYNUCLEOTIDE AMPHIPHILES AND METHODS OF USE THEREOFPharmaceuticalsElicio Therapeutics, Inc.
Jan 9, 20252025/0009888COMPOUNDS INCLUDING A MUTANT KRAS SEQUENCE AND A LIPID AND USES THEREOFPharmaceuticalsElicio Therapeutics, Inc.
Sep 12, 20242024/0299450USES OF AMPHIPHILES IN IMMUNE CELL THERAPY AND COMPOSITIONS THEREFORPharmaceuticalsElicio Therapeutics, Inc.
Nov 23, 20232023/0372299PREPARATION OF TEREVALEFIM AND FORMULATIONS THEREOFPharmaceuticalsANGION BIOMEDICA CORP.
Oct 5, 20232023/0312561SOLID FORMS OF (Z)-METHYL 3-(((4-(N-METHYL-2-(4-METHYLPIPERAZIN-1-YL)ACETAMIDO)PHENYL)AMINO)(PHENYL)METHYLENE)-2-OXO-2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDINE-6-CARBOXYLATE AND SALTS THEREOFPharmaceuticalsANGION BIOMEDICA CORP.
Sep 28, 20232023/0302108ALK POLYPEPTIDES AND METHODS OF USE THEREOFPharmaceuticalsElicio Therapeutics, Inc. · patent 12,370,245 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 7.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ELTX · research, not advice